Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
- PMID: 26386078
- DOI: 10.1309/AJCP51HCGPOPWSCY
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
Abstract
Objectives: Although intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene amplification has been associated with a poor prognosis for primary HER2-positive breast cancer and metastatic HER2-positive breast cancer treated with trastuzumab, the clinicopathologic significance in a setting involving trastuzumab treatment as an adjuvant treatment has not been studied in patients.
Methods: We retrospectively investigated 443 patients with HER2-positive breast cancer treated with surgery, adjuvant chemotherapy, and 1 year of trastuzumab. Three areas that showed different levels of HER2 protein expression were chosen, and silver in situ hybridization was performed.
Results: HER2 regional and genetic heterogeneity was found in 6.2% and 6.8% of tumors, respectively. Both types of heterogeneity were significantly associated with hormone receptor positivity, HER2 immunohistochemistry score of 2+, a low level of HER2 gene amplification, and absence of an extensive intraductal component. Genetic heterogeneity also showed strong correlation with a lower histologic grade. In the hormone receptor-positive group, the regional heterogeneity affected disease-free survival of patients (hazard ratio, 4.869; 95% confidence interval, 1.424-16.646; P = .005), whereas genetic heterogeneity did not.
Conclusions: Evaluation of intratumoral heterogeneity, especially in cases with hormone receptor positivity, may be valuable for assessing the prognosis of HER2-positive patients anticipating treatment with adjuvant systemic therapy and trastuzumab.
Keywords: Adjuvant chemotherapy; Breast carcinoma; Gene amplification; HER2; Heterogeneity; Trastuzumab.
Copyright© by the American Society for Clinical Pathology.
Similar articles
-
HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.Am J Clin Pathol. 2014 Dec;142(6):755-66. doi: 10.1309/AJCPIRL4GUVGK3YX. Am J Clin Pathol. 2014. PMID: 25389328
-
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8. Breast Cancer. 2015. PMID: 23749689
-
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.Am J Clin Pathol. 2015 Aug;144(2):278-88. doi: 10.1309/AJCPIXUYDVZ0RZ3G. Am J Clin Pathol. 2015. PMID: 26185313
-
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541. Oncotarget. 2016. PMID: 27566580 Free PMC article. Review.
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
Cited by
-
Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.J Pers Med. 2024 Apr 28;14(5):467. doi: 10.3390/jpm14050467. J Pers Med. 2024. PMID: 38793049 Free PMC article. Review.
-
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.iScience. 2024 Apr 15;27(5):109750. doi: 10.1016/j.isci.2024.109750. eCollection 2024 May 17. iScience. 2024. PMID: 38711454 Free PMC article.
-
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
-
Machine learning-based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results.Cancer Med. 2024 Feb;13(3):e6946. doi: 10.1002/cam4.6946. Epub 2024 Jan 17. Cancer Med. 2024. PMID: 38234171 Free PMC article.
-
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.NPJ Breast Cancer. 2024 Jan 2;10(1):2. doi: 10.1038/s41523-023-00605-3. NPJ Breast Cancer. 2024. PMID: 38167908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous